BioNTech (BNTX) Stock Forecast, Price & News

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares.
View BNTX analyst ratings or view top-rated stocks.

13 brokerages have issued 1-year target prices for BioNTech's stock. Their BNTX share price forecasts range from $120.00 to $260.00. On average, they expect the company's stock price to reach $172.20 in the next twelve months. This suggests a possible upside of 63.6% from the stock's current price.
View analysts price targets for BNTX or view top-rated stocks among Wall Street analysts.

BioNTech's stock was trading at $150.22 at the start of the year. Since then, BNTX stock has decreased by 29.9% and is now trading at $105.27.
View the best growth stocks for 2023 here.

BioNTech saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 2,020,000 shares, an increase of 5.2% from the April 30th total of 1,920,000 shares. Based on an average trading volume of 699,600 shares, the days-to-cover ratio is presently 2.9 days.
View BioNTech's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our BNTX earnings forecast.

BioNTech SE (NASDAQ:BNTX) released its quarterly earnings results on Monday, May, 8th. The company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $0.18 by $1.87. The business had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.09 billion. BioNTech had a trailing twelve-month return on equity of 32.52% and a net margin of 51.03%. The company's revenue was down 80.0% compared to the same quarter last year. During the same quarter last year, the business earned $15.98 EPS.

ETFs with the largest weight of BioNTech (NASDAQ:BNTX) stock in their portfolio include Direxion mRNA ETF (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), VanEck Biotech ETF (BBH), First Trust NYSE Arca Biotechnology Index Fund (FBT), Franklin Genomic Advancements ETF (HELX) and Loncar Cancer Immunotherapy ETF (CNCR).

33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD).

(BNTX) raised $251 million in an IPO on Thursday, October 10th 2019. The company issued 13,200,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

BioNTech trades on the NASDAQ under the ticker symbol "BNTX."

BioNTech's stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (3.10%), Flossbach Von Storch AG (1.41%), Artisan Partners Limited Partnership (1.07%), BlackRock Inc. (0.79%), Envestnet Asset Management Inc. (0.40%) and Twin Tree Management LP (0.00%).

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BNTX stock can currently be purchased for approximately $105.27.

BioNTech (NASDAQ:BNTX) has a market capitalization of $25.60 billion and generates $18.24 billion in revenue each year. The company earns $9.94 billion in net income (profit) each year or $26.01 on an earnings per share basis.

The company employs 4,530 workers across the globe.

BioNTech's mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The official website for the company is www.biontech.de. The company can be reached via phone at 49-61-31908-40, via email at investors@biontech.de, or via fax at 49-6131-908-4390.